MedTrace Logo

Effect of Bacterial Vaginosis on HIV Susceptibility and Female Genital Immunology

NCT02527941 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-02-10

No results posted yet for this study

Summary

A non-randomized, interventional, longitudinal clinical study to quantify the impact of bacterial vaginosis treatment on HIV susceptibility and genital immunology in Kenyan women.

Conditions

  • Bacterial Vaginosis
  • HIV Infections

Interventions

DRUG

Metronidazole

Participants will be provided with oral metronidazole 400mg po tid for one week, and followed up one month after treatment initiation.

Sponsors & Collaborators

  • University of Toronto

    lead OTHER

Principal Investigators

  • Rupert Kaul, MD/PhD · University of Toronto

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Kenya

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02527941 on ClinicalTrials.gov